Background-Tuberculosis (TB) screening in prevention of mother-to-child transmission (PMTCT) programs is important to improve TB detection, prevention and treatment.
INTRODUCTION
Tuberculosis (TB) is a leading cause of morbidity and mortality among women of childbearing age, and maternal TB during pregnancy and postpartum results in poor maternal and infant outcomes. [1] [2] [3] [4] The World Health Organization (WHO) recommends routine TB symptom screening (fever, cough, night sweats and weight loss) among HIVinfected individuals because of their increased risk of TB. 5 The TB symptom screen is useful to guide clinical evaluation for active TB among those with symptoms and provision of isoniazid preventive therapy (IPT) among patients with a negative symptom screen. 5 Integration of TB screening into prevention of mother-to-child-transmission (PMTCT) programs has been proposed as an effective way to improve TB detection and prevention services for both mothers and infants, but has not been widely implemented. 6 TB screening and prevention should optimally occur during both antenatal and postnatal services; however, there are no evidence-based models for when and how to integrate maternal TB screening. In research cohorts in high HIV and TB prevalence settings, approximately 20% of HIV-infected pregnant women had a positive TB symptom screen, among whom ~5% had active TB disease. [7] [8] [9] Fewer studies have assessed postpartum TB screening at child immunization visits, which may be another opportunity for TB detection and prevention, particularly for HIV-exposed infants. 10 Within a national survey of motherinfant pairs, we assessed the prevalence and correlates of postpartum TB symptoms and TB exposure among HIV-infected mothers at 6-week and 9-month infant immunization visits, in order to inform future scale-up of TB screening and prevention services within PMTCT programs.
METHODS

Study setting
This study was nested within two surveys of the PMTCT program within the maternal child health (MCH) services in Kenya conducted between June and December 2013. The National PMTCT-MCH Survey used probability proportionate to size sampling to select 120 medium (>500 annual antenatal clinic visits) and large volume (>1,000 annual antenatal clinic visits) maternal-child health (MCH) clinics within seven of the 8 geographic regions of Kenya. All mother-infant pairs attending either 6-week or 9-month infant immunization visits were sampled during a single 5-day period. The PMTCT-Nyanza Survey purposively oversampled HIV-infected women and their infants in 30 large volume MCH clinics in Nyanza province, a region of high HIV prevalence, during a single 10-day period. Overall, 141 unique facilities were visited by a mobile study team for both surveys (Figure 1 ).
Participants
For this nested analysis, we included data from HIV-infected women and their infants from the National PMTCT-MCH Survey and the PMTCT-Nyanza Survey. Women who were not willing or able to provide informed consent for the study were excluded.
Procedures
After obtaining informed consent, study staff administered a study questionnaire that included questions about sociodemographic information, HIV history (use of combination antiretroviral therapy (cART), CD4 count, use of co-trimoxazole prophylaxis), prior clinical TB history, TB symptoms, TB exposure in the past 12 months, and use of IPT. TB symptom screening included the WHO 4-part symptom screen (fever, cough, weight loss, night sweats) 5 , as well as other TB symptoms including prolonged cough or fever (>2 weeks), fatigue, anorexia, and hemoptysis. The WHO TB symptom screen was considered positive if a participant reported one or more of the four symptoms. Questions on infant health included sex, birth weight, HIV status, use of antiretroviral prophylaxis, BCG vaccination history, breastfeeding, nonspecific TB symptoms (cough, fever, difficulty breathing, anorexia), and history of hospitalization. Study nurses obtained infant anthropometric measurements (weight and height, and collected a blood sample by heel prick (0.5 ml) for HIV DNA PCR testing. HIV DNA PCR testing was performed at the Centers for Disease Control (CDC)-Kenya Medical Research Institute (KEMRI) HIV research laboratory in Kisumu, Kenya.
National Guidelines
Kenyan National TB guidelines recommend that all HIV-infected patients receive TB symptom screening as part of intensified TB case finding. 11 Patients with a positive TB symptom screen are referred for further evaluation, including sputum smear microscopy for acid fast bacilli (AFB), sputum GeneXpert MTB/RIF (where available) and chest X-ray. Our study did not collect data from study participants on results of these evaluations. WHO and Kenyan National TB guidelines recommend provision of IPT for HIV-infected patients >12 months of age with a negative TB symptom screen, HIV-infected children <12 months of age who have had recent contact with active TB disease with no evidence of TB, and for all children <5 years irrespective of HIV status who have had recent close contact with a case of smear positive TB. 11, 12 However, these guidelines were not widely implemented during the study period.
Statistical Analysis
Statistical analysis was performed using STATA software, version 13 (StataCorp, College Station, Texas). Maternal and infant characteristics at the 6-week and 9-month study visits were described using proportions or medians. Maternal cofactors of maternal positive WHO TB symptom screen were evaluated using univariate logistic regression, with each cofactor as the predictor variable and maternal positive WHO TB symptom screen as the outcome variable. Infant cofactors of maternal positive WHO TB symptom screen were evaluated using univariate logistic or linear regression as appropriate, with maternal positive WHO TB symptom screen as the predictor variable and each cofactor as the outcome variable. All analyses were adjusted to account for clustering within clinics.
Human subjects approval
This study was approved by ethical review boards at the University of Washington, Kenya Medical Research Institute, and the Centers for Disease Control and Prevention.
RESULTS
Of 2,819 women attending 6-week or 9-month immunization visits, 498 were HIV-infected and included in this analysis; 200 women participated in the National PMTCT-MCH Survey and 298 women participated in the PMTCT-Nyanza Survey. Data were available for 260 HIV-infected mothers at the 6-week immunization visit and 238 mothers from the 9-month immunization visit.
Women were a median age of 28 years (Interquartile Range [IQR] 24-32) and had a median of 8 years education (IQR 7-11). Most women were taking cART (63%) and median CD4 count was 483 cells/mm 3 (IQR 346-643 cells/mm 3 ). Eleven percent of women had a history of TB, a median of 4 years (IQR 2-6) prior to enrollment. Eleven percent (52/484) of women reported exposure to a person with active TB in the past year, and 15% (8/52) of TBexposed women reported taking IPT (Table 1) .
Of infants, 49% were male and median birth weight was 3.2 kg (IQR 2.8-3.5 kg). Nearly all infants were BCG-vaccinated (99%), and most (90%) had a BCG scar. Five percent of infants were HIV-infected, and 58% of infants were breastfed. Most infants (97%) received antiretroviral prophylaxis. Median weight-for-age Z score was −0.32 (IQR −1.19-0.51). Seven percent of infants had been hospitalized; none were hospitalized for TB. Nonspecific symptoms that could be TB-related were prevalent among infants, including cough (32%), fever (22%), difficulty breathing (10%), and anorexia (7%). Infants at 9 months of age had a higher prevalence of cough (40% vs 25%, p=0.007), fever (31% vs 15%, p<.001), and anorexia (13% vs 2%, p<.001) compared to infants at 6 weeks of age (Table 1) .
Thirty-three percent of women had a positive WHO TB symptom screen, reporting either current cough, fever, weight loss or night sweats. The most prevalent WHO TB symptom was cough (19%), followed by fever (14%), weight loss (11%), and night sweats (9%). Positive maternal WHO TB symptom screen was associated with household crowding (≥5 vs. ≤4 people in home) [OR=1.14 (1.00-1.29), p=0.05] and history of TB disease [OR=1.66 (1.03-2.68), p=0.04] but not with partner HIV status or reported TB exposure. Women with a positive WHO TB symptom screen had a lower median CD4 count (454 vs 498, p=0.06). Infants born to a mother with a positive WHO TB screen were more likely to have HIV infection (7.6% vs. 2.8%, p=0.02). This association remained significant in multivariate analyses adjusted for maternal cART and infant antiretroviral prophylaxis [OR 3.16 (1.36-7.37), p=0.008]. Mothers with a positive WHO TB screen were more likely to have infants with nonspecific TB symptoms, including cough (44% vs 26%, p=.003), fever (30% vs 19%, p=0.05), difficulty breathing (16% vs 7%, p=0.01) and anorexia (11% vs 5%, p=0.005) ( Table 2 ). Our findings were consistent in a multivariable model adjusting for geographic region and clinic size.
DISCUSSION
In this national survey of 141 MCH clinics, we found that a third (33%) of postpartum HIVinfected women had a positive WHO TB symptom screen at infant immunization visits. Eleven percent of HIV-infected women reported known TB exposure, of whom few received IPT.
The prevalence of WHO TB screen positivity among postpartum HIV-infected women in this study (33%) was higher than most prior studies in pregnant HIV-infected women (~20%) (Figure 2 ). 7-9, 13-16 TB symptoms may be less frequent in pregnancy than postpartum due to immunologic and physiologic changes. 17, 18 Zenner et al. observed a higher incidence of TB disease in the first 6 months postpartum compared to pregnancy and hypothesized that this may reflect subclinical TB disease during pregnancy that becomes clinically-apparent in the postpartum period. 19 Other studies have noted that non-specific or absent symptoms in pregnancy can lead to delays in TB diagnosis. 20, 21 TB symptom screening during the postpartum period may improve diagnostic yield to identify TB disease compared to screening during pregnancy, which has only modest sensitivity between 28 and 50%. [7] [8] [9] 13 Variable performance of the WHO TB symptom screen has been observed, with decreased sensitivity in the context of cART and early TB disease. 7, 22, 23 To our knowledge, performance of the WHO TB symptom screen during the postpartum period has not been previously evaluated. Our data suggest that postpartum TB screening may be useful to consider. Further studies to compare performance of TB screening during pregnancy and postpartum and to estimate incremental benefit and cost-effectiveness of postpartum TB screening will be helpful to determine its role in PMTCT programs.
We found that positive maternal WHO TB screen was associated with history of prior TB, household crowing, and immunosuppression, which are known risk factors for active TB. [24] [25] [26] [27] We additionally observed an association between a positive maternal WHO TB screen and infant HIV infection. Maternal TB disease has previously been shown to be an independent risk factor for infant HIV infection, which may be mediated by immune activation and increased HIV replication. 28 A positive maternal WHO TB screen in our cohort may be a proxy for maternal TB disease or be associated with other mother-to-child HIV transmission risk factors that we were not able to adjust for, such as maternal viral load. However, the association between maternal TB symptoms and infant HIV infection remained significant in multivariable analyses adjusted for use of maternal cART and infant antiretroviral prophylaxis. Maternal TB symptoms were also associated with infant nonspecific TB symptoms, including cough, difficulty breathing, fever, and anorexia, which may represent some cases of undiagnosed infant TB. Older infants were more symptomatic at 9 months compared to infants screened at the 6-week immunization visit, which may represent a missed opportunity for infant TB prevention through early maternal TB diagnosis and IPT administration to TB-exposed infants. Infant TB disease is often not recognized clinically and has high fatality, though IPT is effective to prevent TB in young children with a known TB contact. 29, 30 Our study suggests that integration of maternal TB 
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Few women received IPT in this study, which is consistent with limited implementation of IPT observed in high TB burden countries. 31 IPT is an effective intervention to prevent TB disease; in a modeling study, treatment of latent infection had higher impact on decreasing global TB incidence compared to improved vaccinations or diagnostics. 32 Lack of IPT implementation is due to many factors, including clinician decision-making, poor dissemination of local guidelines and erratic drug supply chain. 33 Improved uptake of IPT is a key priority identified in Kenya's National Tuberculosis, Leprosy, and Lung Health strategic plan. 34 Clinical providers may be hesitant to use IPT among pregnant and postpartum women given lack of adequate safety data and prior reports of maternal deaths due to hepatotoxicity in pregnancy and postpartum. 35 An ongoing clinical trial (IMPAACT 1078) that assesses safety and toxicity of IPT during pregnancy and postpartum, will better inform future use of IPT in this population. 36 Our study had several strengths and limitations. In the context of a national survey, our study presented data for a large number of postpartum HIV-infected women in Kenya. Our data were not nationally representative since we included the PMTCT-Nyanza Survey to increase our sample size of HIV-infected women. Clinical and microbiologic TB diagnostic data were not available for mothers or infants; therefore we could not assess performance of the WHO TB symptom screen for TB diagnosis in the postpartum period or assess if infants with nonspecific TB symptoms had TB disease. Our data on IPT use was limited to women with known TB exposure, which may have underestimated overall IPT use.
In conclusion, we found that postpartum HIV-infected mothers in Kenya frequently reported TB exposure and positive TB symptom screen, but few received IPT. Maternal positive TB symptom screen was associated with infant HIV and nonspecific infant TB symptoms. Integration of maternal TB screening and prevention into PMTCT programs may improve maternal and infant outcomes. Proportion of HIV-infected women with positive WHO TB symptom screen during pregnancy (%, 95% CI) in published studies to date. 
